BiotechTube

Dienogest (BAY86-5258, Visanne)

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Endometriosis Associated Pelvic Pain

Conditions

Endometriosis Associated Pelvic Pain

Trial Timeline

May 13, 2022 → Sep 23, 2024

NCT ID
NCT04808843

About Dienogest (BAY86-5258, Visanne)

Dienogest (BAY86-5258, Visanne) is a pre-clinical stage product being developed by Bayer for Endometriosis Associated Pelvic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT04808843. Target conditions include Endometriosis Associated Pelvic Pain.

Hype Score Breakdown

Clinical
5
Activity
2
Company
7
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT04808843Pre-clinicalCompleted

Competing Products

20 competing products in Endometriosis Associated Pelvic Pain

See all competitors
ProductCompanyStageHype Score
ASP1707 + Placebo + Leuprorelin acetateAstellas PharmaPhase 2
52
40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateSumitomo PharmaPhase 3
77
SHR7280 TabletsJiangsu Hengrui MedicinePhase 1
33
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
33
SHR7280 + Placebo oral tabletJiangsu Hengrui MedicinePhase 1/2
41
SHR7280 Tablet + SHR7280 Placebo TabletJiangsu Hengrui MedicinePhase 1
33
Placebo + ElagolixAbbViePhase 2
52
Elagolix + Placebo + Combined Oral ContraceptiveAbbViePhase 3
77
Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETAAbbViePhase 3
77
ElagolixAbbViePhase 3
77
elagolix + estradiol/norethindrone acetate (E2/NETA)AbbViePhase 3
77
Elagolix + placeboAbbViePhase 2
52
ElagolixAbbViePhase 3
77
Elagolix + Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) + Placebo to Elagolix + Placebo to DMPA-SCAbbViePhase 2
52
elagolixAbbViePhase 3
77
ElagolixAbbViePhase 3
77
Leuprorelin Acetate Depot + Elagolix + Placebo to Elagolix + Placebo to Leuprorelin AcetateAbbViePhase 2
52
Gefapixant + Placebo + NaproxenMerckPhase 2
52
BGS649 + PlaceboNovartisPhase 2
52
Active treatment with a high dose of BGS649 + Active treatment with a low dose of BGS649 + Placebo treatment to blind studyNovartisPhase 2
52

Other Products from Bayer

TelmisartanApproved
82
Clotrimazole vaginal tablet + FluconazoleApproved
82
Levitra (Vardenafil, BAY38-9456)Approved
82
Avelox (Moxifloxacin, BAY12-8039) + Amoxicillin clavulanic acidApproved
82
Rivaroxaban 20 MG + WarfarinApproved
82